



**NIH AIDS Reagent Program**  
20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

## DATA SHEET

<b>Reagent:</b>	Darunavir (Prezista, TMC 114)
<b>Catalog Number:</b>	11447
<b>Lot Number:</b>	A14JS2686
<b>Release Category:</b>	E
<b>Provided:</b>	20 mg
<b>Chemical Name:</b>	Carbamic acid, N-[(1S,2R)-3-[[[4-aminophenyl)sulfonyl]92-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3a5,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
<b>Empirical Formula:</b>	C <sub>27</sub> H <sub>37</sub> N <sub>3</sub> O <sub>7</sub> S
<b>Molecular Weight:</b>	547.66
<b>CAS Num:</b>	635728-49-3
<b>Purity:</b>	91.9%
<b>Solubility:</b>	Approximately 0.16 mg/ml in water
<b>Description:</b>	Darunavir is a protease inhibitor.
<b>Mechanical Action:</b>	Darunavir, also known as Prezista or TMC 114, is a nonpeptidic protease inhibitor (PI) that inhibits the replication of HIV-1 in infected cells. Darunavir acts by selectively inhibiting the cleavage of HIV-1 encoded Gag-Pol polyproteins in infected cells and preventing the formation of mature virus particles. Darunavir is highly effective against both wild-type and PI-resistant HIV. <b>Warning: Reagent is harmful if inhaled or in contact with skin.</b>

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

<b>Special Characteristics:</b>	<a href="#">Certificate of Analysis</a> <b>All recipients must complete the TMC114 Addendum prior to receipt of this reagent.</b>
<b>Recommended Storage:</b>	Room temperature. Once resuspended, working aliquots can be stored at –20°C.
<b>Contributor:</b>	Janssen Pharmaceuticals
<b>NOTE:</b>	Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Darunavir (Cat# 11447) from Tibotec, Inc." <b>This compound is limited to 40 mg per requester per year.</b> <b>Requesters from commercial institutes should be directed to Dr. Richard Hoetelmans: <a href="mailto:rhoetelm@tibbe.inj.com">rhoetelm@tibbe.inj.com</a>, tel (+) 32 15 461 041, fax (+) 32 15 444 292, Tibotec BVBA, Generaal De Wittelaan L11/B3 Mechelen, Belgium 2800.</b> <b>Recipient agrees that the reagent (Darunavir) use is permitted only as a standard for in vitro and/or studies in animals for inhibition of HIV replication.</b>
<b>Required Form</b>	TMC114 Form.pdf
<b>Last Updated</b>	April 17, 2018

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.